Related references
Note: Only part of the references are listed.Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study
Andre Mueller et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Impact of switching to a heat-not-burn tobacco product on CYP1A2 activity
Angela van der Plas et al.
TOXICOLOGY REPORTS (2020)
Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles
Talakad G. Lohith et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
[18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease
Sandra Sanabria Bohorquez et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Tau PET imaging in neurodegenerative tauopathies-still a challenge
Antoine Leuzy et al.
MOLECULAR PSYCHIATRY (2019)
Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (PET) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2A PET Ligand
Lei Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Effect of nicotine on cytochrome P450 1A2 activity
Janne Hukkanen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
PET radiotracers: crossing the blood-brain barrier and surviving metabolism
Victor W. Pike
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
Heiko Braak et al.
ACTA NEUROPATHOLOGICA (2006)
Share Paper
